Skip to content

Key resources

  • Bibliography
    Bibliography
  • Health promotion
    Health promotion
  • Health practice
    Health practice
  • Programs
    Programs
  • Conferences
    Conferences
  • Courses
    Courses
  • Funding
    Funding
  • Jobs
    Jobs
  • Organisations
    Organisations
  • Health Services MapHealth Services Map
Australian Indigenous HealthBulletin Alcohol and other drugs knowledge centre Yarning Places
 
  • Home
    • » Key resources and services
      • » Programs and projects
        • » Immunogenicity, Carriage and Otitis Media Outcomes of Pneumococcal Conjugate Vaccines Phid-CV and 13PCV in Sequence or Alone in High-Risk Indigenous Infants: A Randomised Controlled Trial

Immunogenicity, Carriage and Otitis Media Outcomes of Pneumococcal Conjugate Vaccines Phid-CV and 13PCV in Sequence or Alone in High-Risk Indigenous Infants: A Randomised Controlled Trial

 

Overview

This randomised control trial aims to determine whether early commencement of a sequential schedule of two pneumococcal conjugate vaccines, Pneumococcal Haemophilus influenzae protein D-conjugate vaccine (PHiD-CV or Synflorix) and 13-valent pneumococcal conjugate vaccine (PCV13 or Prevenar13), given in sequence at one, two, four (PHiD-CV), and 6 months (PCV13), gives greater protection against otitis media compared to either PCV13-alone or PHiD-CV-alone at two, four, and six months.

The project also aims to determine if a combination of pneumococcal vaccines is superior to single vaccines in terms of immunogenicity, nasopharyngeal carriage of otitis media pathogens and all-cause otitis media in Aboriginal and Torres trait Islander infants living in remote communities.

The project is funded by the National Health and Medical Research Council (NHMRC) and headed by Menzies School of Health Research.

Contacts

Professor Amanda Leach
Chief Investigator
Menzies School of Health Research
John Mathews Building (JMB)
Building 58, Royal Darwin Hospital Campus
Rocklands Drive
Tiwi NT 0810

PO Box 41096
Casuarina NT 0811
Email: amanda.leach@menzies.edu.au

Related publications

Leach AJ, Mulholland EK, Santosham M, Torzillo PJ, Brown NJ, McIntyre P, Smith-Vaughan H, Skull S, Balloch A, Andrews R, Carapetis J, McDonnell J, Krause V, MorrisPS (2015)

Pneumococcal conjugate vaccines PREVenar13 and SynflorIX in sequence or alone in high-risk Indigenous infants (PREV-IX_COMBO): protocol of a randomised controlled trial.

BMJ Open; 5(1): e007247

Retrieved 16 January 2015 from http://dx.doi.org/10.1136/bmjopen-2014-007247

Links

 
Last updated: 17 March 2017
 
Return to top